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Abstract
Background:  Airways repair is critical to lung function following transplantation. We
hypothesised that the stem cell factor (SCF) could play a role in this setting.
Methods: We studied 9 lung transplant recipients (LTx recipients) during their first year postgraft,
and evaluated SCF mRNA expression in bronchial biopsy specimens using on-line fluorescent PCR
and SCF protein levels in bronchoalveolar lavage (BAL) and serum using ELISA. The expression of
SCF receptor Kit was assessed using immunostaining of paraffin-embedded bronchial sections.
Results: SCF mRNA was highly expressed during the early postgraft period [Month (M)1-M3]
(300% increase vs controls: 356 vs 1.2 pg SCF/µg GAPDH cDNA, p < 0.001) and decreased
thereafter (M4-M12: 187 pg/µg), although remaining at all times 10–100 times higher than in
controls. While SCF protein levels in BAL were similar in LTx recipients and in controls, the SCF
serum levels were at all times higher in LTx recipients than in controls (p < 0.05), with no
relationship between these levels and the acute complications of the graft. Finally, Kit was strongly
expressed by the mast cells as well as by the bronchial epithelium of LTx recipients.
Conclusion: SCF and Kit are expressed in bronchial biopsies from lung transplant recipients
irrespective of the clinical status of the graft. A role for these factors in tissue repair following lung
transplantation is hypothesised.
Background
Injury processes of various types can damage a grafted
organ. Some are due to the surgical procedure itself-the
section of vessels and nerves and, for lung transplants,
conducting airways. Others are inflammatory in nature,
due to reperfusion of the graft or early allogeneic reac-
tions. The lack of efficient tissue repair mechanisms
would severely impair graft functioning. The restoration
of transplanted airways involves a variety of cell types:
local progenitors, found mainly among basal and Clara
cells [1-3], and host stem cells from the bone marrow, a
rich reservoir of progenitors for different cell types includ-
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ing mast cells [4-6]. Experimental studies in murine mod-
els provide evidence that bone marrow stem cells can
differentiate into type I and type II pneumocytes and
bronchial epithelial cells [5,7]. The ability of such cells to
engraft into the human lung is still controversial although
studies after hematopoietic stem cell transplantation in
humans show evidence of donor-derived cells (chimer-
ism) in the lung [8,9]. In this context, SCF is a key factor
in mobilisation of stem cells from bone marrow where it
facilitates egress from the marrow to the circulation [10].
On the other hand, there is some evidence for the involve-
ment of local progenitor cells in repair processes follow-
ing tissue injury in murine models [11-13] as well as in
human situations [14,15]. The SCF/Kit pathway has also
been shown to play a key role in these latter.
To our knowledge, SCF production has never been evalu-
ated in the lung in settings other than asthma, where it is
markedly upregulated [16]. More specifically, it has never
been evaluated in the context of solid organ transplanta-
tion. We hypothesised that it might be produced soon
after transplantation to participate in airway tissue repair.
We therefore evaluated SCF mRNA expression in bron-
chial biopsy specimens and SCF protein expression in
bronchoalveolar lavage (BAL) and serum during a one-
year follow-up of human LTx recipients. We also assessed
SCF receptor Kit expression in bronchial epithelium using
immunodetection. Finally, because SCF is a well-known
mast cell growth factor (for review see [17,18]), we also
quantified the number of mast cells infiltrating the air-
ways.
Methods
Study population
Nine (3 single and 6 double) lung transplant recipients (3
males, 6 females), aged 41 (median; range: 22–60 years),
were included into this study. Their initial diagnoses were
cystic fibrosis (n = 3), emphysema (n = 2), diffuse bron-
chiectasis (n = 2), pulmonary artery hypertension associ-
ated with systemic sclerosis (n = 1), and
lymphangioleiomyomatosis (n = 1). All patients were ini-
tially placed on an immunosuppressive regimen includ-
ing cyclosporin A, azathioprine and prednisone, until the
third episode of acute lung rejection (ALR) after which
cyclosporin A was switched to tacrolimus and azathio-
prine to mycophenolate mofetil. In addition to clinical
and functional evaluation, fiberoptic bronchoscopy with
bronchoalveolar lavage (BAL), transbronchial biopsies
and proximal bronchial biopsies were routinely per-
formed in each patient either to detect asymptomatic
complications at day 30 after surgery (then every month
during the first 6 months and every 6 months thereafter)
or as part of the routine procedure for the diagnosis of
complications suspected on clinical and/or functional
grounds. One patient died 8 months after the transplant
of infectious (Aspergillus) complications. None of the
patient was diagnosed with bronchiolitis obliterans syn-
drome (BOS) during the study period but 4 of them sub-
sequently developed this complication between 15 and
33 months post-transplantation, leading to death in two.
Control subjects (4 males and 5 females, aged 25
(median; range: 21–38 years) were all healthy volunteers.
The study was approved by the local Ethics committee,
and all patients and control subjects provided written
informed consent.
Tissue specimens
Bronchial biopsy specimens were fixed in 10% buffered
formalin and paraffin-embedded. They were cut into four-
µm sections for morphological and immunohistochemi-
cal evaluation. An additional biopsy sample was snap-fro-
zen in liquid nitrogen for subsequent RNA extraction.
Four to six serial samples per patient, recovered during the
first year post-transplantation, were evaluated.
RNA extraction and reverse transcription
Total RNA was extracted from biopsy specimens with
TriReagent® (Molecular Research Center Inc., Cincinnati,
OH, USA). Isolated RNA was diluted in RNase-free water
and quantified by absorbance measurement at 260 nm.
Two µg of total RNA were incubated with 0.5 µg of ran-
dom primers for 5 min at 70°C, and allowed to cool
down at room temperature. RNA was subsequently
reverse-transcribed in 1× reverse transcription (RT) buffer
(75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, and 50
mM Tris-HCl, pH8.3), containing 1 unit/µl RNasin ribo-
nuclease inhibitor, 1 mM of each dNTP, and 10 units/µl
RNase H(-)-Moloney leukemia virus reverse transcriptase
(all reagents from Promega, Madison, WI, USA). The reac-
tion was conducted for 1 h at 37°C, and then the reverse
transcriptase was heat-inactivated at 99°C for 5 min.
Quantification of SCF cDNA
Reverse transcribed cDNAs were amplified by on-line flu-
orescent PCR (LightCycler™-SYBR GreenI, Roche Diagnos-
tics), with primers leading to single 149-bp and 240-bp
PCR products for quantification of SCF and GAPDH (used
as a housekeeping gene) cDNAs, respectively. PCR reac-
tions were performed in 1× PCR reaction buffer [2 µl of
the reaction mix, containing FastStart Taq DNA polymer-
ase, dNTP mix, SYBR Green I, 3 mM MgCl2 (Roche Diag-
nostics)], and 10 pmol of each primer:
SCF amplification: sense primer 5'-TGGATAAGCGAGAT-
GGTAGT-3'antisense primer 5'-TTTTCTTTCACGCACTC-
CAC-3', GAPDH amplification:sense primer 5'-
GGTGAAGGTCGGAGTCAACGGA-3' antisense primer5'-
GAGGGATCTCGCTCCTGGAAGA-3', in a 20 µl final vol-
ume for 35 cycles. Each cycle consisted of 15 sec denatur-Respiratory Research 2006, 7:90 http://respiratory-research.com/content/7/1/90
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ation at 95°C, 10 sec annealing (at 53°C for SCF cDNA
amplification and 60°C for GAPDH) and 10 sec extension
at 72°C. Amplified SCF and GAPDH cDNAs and standard
SCF and GAPDH cDNAs were analysed on-line by fluores-
cence (LightCycler™, Roche Diagnostics).
The standard SCF and GAPDH cDNA came from pulmo-
nary fibroblast total cDNA. After amplification by PCR,
with the primers described above, the 149 bp- and 240
bp-PCR products were electrophoresed on a 2% agarose
gel, stained with ethidium bromide, purified on QIAEX II
(QIAEX II gel extraction kit, QIAGEN, Courtaboeuf,
France), and quantified by fluorescence (PicoGreen®,
Molecular Probes Inc.) according to a standard curve
obtained with a double-stranded phage λ DNA (0.005–1
µg/ml). The purified SCF cDNA and GAPDH cDNA were
used to establish a standard curve from 1 to 300 fg/ml.
Quantification of SCF cDNA (pg) was normalised to the
GAPDH cDNA measurement. Results were expressed as pg
SCF cDNA/µg GAPDH cDNA.
Soluble SCF protein measurement in BAL and serum
A sensitive ELISA procedure quantified immunoreactive
SCF released into patients' BAL fluid and serum. It used a
capture anti-human SCF monoclonal antibody (R&D Sys-
tems Europe, Abingdon, UK, clone 13302) and an anti-
human SCF biotinylated polyclonal antibody (R&D Sys-
tems Europe), revealed by extravidin-horseradish peroxi-
dase and a 3,3',5,5'-tetramethylbenzidine liquid substrate
system (Sigma Chemicals, St Louis, MO, USA). Standard
curves were generated with recombinant human SCF
(R&D Systems Europe) diluted in fœtal calf serum. They
were linear from 16 to 500 pg/ml. Eight normal blood
donors provided serum for control purposes. Soluble SCF
concentrations were expressed as pg/ml of BAL fluid or
serum.
Kit immunodetection
Four- µm sections of paraffin-embedded biopsies were cut
and used for immunohistochemistry. Briefly, tissue sec-
tions previously deparaffinised in toluene and rehydrated
through graded concentrations of ethanol, were incubated
for 60 min at room temperature with a primary polyclonal
rabbit anti-human CD117 (Kit) (1/100) (Santa Cruz Bio-
technology, Inc; CA, USA). After two washings with Tris
buffer at pH 7.6, staining was revealed according to the
avidin-biotin method using a LSAB AP kit (Dako Corp;
Carpinteria, CA, USA) and FastRed as a substrate. Tissue
sections were finally counterstained with hematoxylin
and mounted with Ultramount medium (Dako Corp; CA,
USA). To ensure the anti-Kit binding specificity, two types
of negative controls were used: 1) by omitting the primary
antibody and 2) by preincubating the primary antibody
with a specific blocking peptide (sc-168 P, Santa Cruz Bio-
technology, Inc; CA, USA).
Mast cell counts
The immunodetection of mast cells was similar to that
described above with the primary antibody being a mon-
oclonal mouse anti-human tryptase (0.25 µg/ml, Dako
Corp; CA, USA). Results are expressed as the number of
tryptase-positive cells per mm2 of bronchial structure.
Statistical analysis
All results are expressed as median values (SCF mRNA,
SCF protein levels, mast cell numbers) collected during
two different periods of time: M1-M3 (months 1 to 3 post-
graft, during which the immunosuppressive regimens are
usually the most intensive) and M4-M12 (months 4 to 12
post-graft, during which corticosteroids doses are usually
tapered in case of an uneventful evolution of the graft).
Comparisons were made using the non-parametric Mann
Whitney U-test for unpaired series. A p value <0.05 was
considered significant.
Results
SCF mRNA
High levels of SCF mRNA expression were observed in the
airways of every lung transplant recipient. This expression
was particularly marked during the early post-transplant
period (M1-M3), when it was 300% of the level in con-
trols (356 pg SCF/µg GAPDH (range: 59–1826) in
patients and 1.2 pg SCF/µg GAPDH mRNA (range: 0.4–
5.8) in controls, p < 0.001) (Figure 1). SCF expression
thereafter decreased in lung transplant recipients (M4-
M12: 187 pg/µg GAPDH mRNA (range: 10–987), p < 0.05
vs M1-M3) but remained 10–100 times higher in patients
than controls throughout this period (Figure 1). We found
no statistical relation between clinical status and SCF
mRNA expression, which remained at comparable levels
when the patient's condition was stable and during acute
complications.
SCF protein
It was detected in every BAL sample taken from LTx recip-
ients. Its concentration remained comparable to controls
throughout the study period (70 pg/ml (range: 34–182)
during M1-M3, 67 pg/ml (range: 35–144) during M4-
M12 and 58 pg/ml (range: 1–90) in controls, NS for all
comparisons). In contrast, serum SCF levels remained at
all times higher in LTx recipients than in controls (142 pg/
ml (range: 104–265) during M1-M3, 193 pg/ml (range:
67–338) during M4-M12 and 53 pg/ml (range: 28–174)
in controls, p < 0.05 controls vs both post-transplant peri-
ods) (Figure 2).Respiratory Research 2006, 7:90 http://respiratory-research.com/content/7/1/90
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Kit expression
SCF receptor Kit could be evaluated in 5 of 9 LTx recipi-
ents. Figure 3 shows a marked staining of the mast cells as
well as of the bronchial epithelium with a clear immu-
nolocalisation on some basal and some ciliated epithelial
cells (Figure 3).
Tryptase-positive cells
Non degranulated tryptase-positive cells were observed in
almost all biopsy specimens from LTx recipients. They
were mainly located in the bronchial submucosa but also
infiltrated the bronchial epithelium (Figure 4). In the
early post-transplant period, mast cell counts were not dif-
ferent in patients and controls (36 (range: 0–215) vs 30
(range: 7–71)/mm2 in the M1-M3 period and in controls,
respectively; NS). They subsequently increased signifi-
cantly in LTx recipients: 71 (range 2–224)/mm2 during
M4-M12 (p  < 0.05 vs M1-M3 and vs controls). This
increase appeared independent of patients' clinical condi-
tion (stable condition or acute complications).
Discussion
Our study shows that SCF was highly expressed in 9 of 9
lung transplant recipients irrespective of their clinical sta-
tus (infection, rejection). The level of this expression is
remarkable, being 300-times greater than in controls in
the early post-graft period and albeit decreasing thereafter,
remaining at least 10-fold over the control values until the
end of the first year post-transplant. To our knowledge,
such high levels of SCF transcripts have never been
reported so far in human airways. They are striking given
the high corticosteroid doses administered to the patients
during the early post-transplant period, knowing the
usual inhibition of SCF expression by this drug as
reported in asthma patients treated with glucocorticoids
[16] as well as in pulmonary fibroblasts in vitro [19]. The
only inflammatory airway condition in which SCF expres-
sion been reported before is asthma [16,20], albeit with
levels largely lower than those reported in this study.
None of the underlying diseases which indicated pulmo-
nary transplantation in our patients has ever been
reported to be associated with SCF airway expression.
With respect to SCF protein, although it was detected in
the BAL fluid of every LTx recipients, it remained at levels
comparable with those of controls. In contrast, SCF serum
levels were significantly higher in LTx recipients than in
controls. One possible explanation for the apparent dis-
crepancy between SCF BAL and serum levels is that
SCF protein levels in serum Figure 2
SCF protein levels in serum. SCF protein levels were 
assessed by ELISA in serum from control subjects (Control) 
and lung transplant recipients at Months (Mo) postgraft 1 to 
3 (M1-M3), and 4 to 12 (M4-M12). Results are expressed as 
pg/ml, and represented as individual (symbols) and median 
values (bold line) (NS; non-significative, *; p < 0.05, **; p < 
0.01, ***; p < 0.001).
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SCF mRNA expression in lung transplant recipients Figure 1
SCF mRNA expression in lung transplant recipients. SCF 
mRNA was quantified after total RNA reverse transcription 
by on-line fluorescent PCR in biopsy specimen from control 
subjects (Control) and lung tranplant patients at Months 
(Mo) postgraft 1 to 3 (M1-M3), and 4 to 12 (M4-M12). 
Results were normalised to GAPDH mRNA expression, and 
expressed in pg/µg as the ratio [SCF mRNA]/[GAPDH 
mRNA]. Symbols denote individual episodes ( : stable con-
dition, ❍  : acute lung rejection, × : infection). Median values 
are also shown (bold line) (NS; non-significative, *; p < 0.05, 
**; p < 0.01, ***; p < 0.001).
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inflammatory alveolar cells, the main cell compartment
sampled by BAL, are not its main source in the trans-
planted lung. Although our study does not allow us to
draw conclusions about the nature of producing cells, we
can hypothesise that bronchial cells are also at least partly
involved in this production since all resident lung cells
have this ability i.e. normal epithelial cells, smooth mus-
cle cells and fibroblasts [20-22].
The role of SCF in this context can only be speculative. In
our small cohort of patients, we found no relationship
between mRNA levels and the current clinical situation,
particularly acute complications of the graft. It was highly
and early expressed even in subjects in stable condition.
One hypothesis is that the SCF produced locally might
play a role in inflammatory/repair processes following
transplantation. Along with this hypothesis, it is of inter-
est to note the expression of the SCF receptor Kit, which
we have shown in the bronchial epithelium of LTx recipi-
ents. The SCF/Kit pathway, functioning in an autocrine
and/or paracrine manner, has clearly been implicated in
repair processes taking place after different types of tissue
injury in animal models [11-13] as well as in humans
[14,15]. Alternatively, SCF having the ability to mobilise
stem cells of hematopoietic origin [10,23], it could partic-
ipate in their recruitment to the lung, in keeping with a
recent experimental model of lung injury showing a par-
tial pulmonary reconstitution by originally hematopoietic
cells [6]. Indeed, some allografts exhibit a low but consist-
ent chimerism [24-26]. This phenomenon has been
recently confirmed in human lung allografts [27,28]. SCF
might be one of the factors involved in the mobilisation
Photomicrograph of Kit expression in LTx recipients biopsy sections Figure 3
Photomicrograph of Kit expression in LTx recipients biopsy sections. Kit was immunodetected using a polyclonal rabbit anti-
human CD117 (Kit) in bronchial biopsy specimen from LTx recipients in mast cells (arrow head) and epithelial cells (magnitude 
×40).Respiratory Research 2006, 7:90 http://respiratory-research.com/content/7/1/90
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and homing of hematopoietic lung progenitors to the
injured/repairing zone. On the other hand, SCF is the
main chemotactic, activation and growth factor for mast
cells [17,18]. Of note is the fact that we have shown a cer-
tain degree of mast cell infiltration of transplanted airways
particularly during the second post-transplant period
(M4-M12). This delay might be partly explained by the
high doses of corticosteroids included in the early post-
graft immunosuppressive regimens, to which mast cells
are known to be highly sensitive. In any case, mast cells
can exert strong beneficial effects in inflamed organs
through the release of a wide range of mediators involved
in different aspects of wound healing [29-31]. Conversely,
they have also been implicated in various fibrotic proc-
esses [32-35] as well as in chronically rejected lungs
[36,37].
Conclusion
Whether mast cells, which infiltrate the transplanted lung,
are innocent bystanders attracted by potent chemotactic
factors or are actively recruited for specific purposes is
presently unknown. Only the continued follow-up of our
patients and the repeated evaluation of these factors over
time will tell us about the potential relationship between
SCF expression, mast cell presence in the airways and lung
transplant outcome.
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